arrow
A

Alison Skrinar

Ultragenyx Pharmaceutical
H指数:25
被引数:4,125

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Effect of Burosumab Compared With Conventional Therapy on Younger vs Older Children With X-linked Hypophosphatemia

与常规疗法相比,Burosumab对X连锁低磷血症的年龄较小和年龄较大的儿童的影响

2022-05-0945
OA
Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked Hypophosphatemia
2021-01-2331
OAAI
Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial
LANCET
IF88.5
2019-06-01242
OAAI
Enzyme-Replacement Therapy in Life-Threatening Hypophosphatasia
2012-03-08437
OAAI
A Randomized Study of Alglucosidase Alfa in Late-Onset Pompe's Disease.
2010-04-15545
OA
Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease
2009-03-01249
PREAI